Industry Newscircular rnacar tlillylipid nanoparticles
Lilly Acquires Orna Therapeutics For $2.4 Billion
5.6
On February 9, Eli Lilly announced an agreement to acquire Orna Therapeutics in a deal valued at up to $2.4 billion in cash, and its shares rose more than 3% in morning trading. Orna’s circular-RNA platform aims to enable patients’ cells to generate therapies in vivo; its lead candidate ORN-252 is an early-stage CAR-T targeting CD19 delivered via novel lipid nanoparticles.
Key Points
- 1Announces acquisition of Orna Therapeutics for up to $2.4 billion in cash consideration
- 2Secures circular-RNA platform enabling in vivo cell-generated therapies, potentially avoiding ex vivo cell engineering
- 3Signals diversification beyond weight-loss into oncology and gene therapies, informing investment and R&D priorities
Scoring Rationale
Notable strategic acquisition with credible company announcement, but limited AI/ML relevance reduces broader industry significance.
Sources
Public references used for this report.
Practice interview problems based on real data
1,625 SQL & Python problems across 15 industry datasets — the exact type of data you work with.
Try 250 free problems
